RELMADA THERAPEUTICS INC

The following additional risk factor has been identified since those presented under Part I, Item 1A of our Form 10-K for the year ended December 31, 2023.

RISKS RELATED TO OUR BUSINESS

There is doubt about our ability to continue as a going concern.

As of September 30, 2024, the Company had an accumulated deficit of $622,224,899. Losses have principally occurred as a result of the substantial resources required for research and development of the Company’s product candidates which included the general and administrative expenses associated with its organization and product development as well as the lack of sources of revenues until such time as the Company’s products are commercialized. These factors raise substantial doubt about the Company’s ability to continue as a going concern for the 12 months from the issuance date of these unaudited condensed consolidated financial statements for the quarter ended September 30, 2024. These financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of these uncertainties. Management intends to pursue additional funding and implement its strategic plan to allow the opportunity for the Company to continue as a going concern, however, there cannot be any assurance that we will be successful in doing so.